Salute e Benessere

Novo Nordisk A/S: Ozempic® receives EU recommendation in peripheral arterial…

Pending a decision from the European Commission, Ozempic ®(once-weekly semaglutide) will have the broadest approved label in the glucagon-like peptide-1 receptor agonist (GLP-1 RA) class, demonstrating improvements in blood sugar, weight, cardiovascular (CV) events, chronic kidney disease and peripheral arterial disease (PAD) functional outcomes 1.Ozempic ®is the first and only glucose-lowering treatment with proven functional benefits in people with type 2 diabetes and PAD 1...
Nasdaq GlobeNewswire
23/06/2025

SciBase resolves on a directed share issue of approximately SEK 11 million

Background and motives Background and motives SciBase is a medical technology company specializing in early detection and prevention in dermatology through the commercialization of Nevisense. Nevisense is a patient-centric platform that combines AI (artificial intelligence) and advanced EIS (electrical impedance spectroscopy) technology to increase diagnostic accuracy and thereby ensure the prevention of skin diseases. By enabling doctors to make accurate diagnoses with greater precision,...
PR Newswire
23/06/2025

Kenya IVD Market to Reach $68.66 Million by 2032, Growing at 3.2% CAGR, Says…

The growth of the Kenya IVD market is primarily driven by the nation's substantial burden of infectious diseases, including HIV/AIDS, tuberculosis, and malaria, which continues to necessitate advanced diagnostic solutions. Kenya faces critical healthcare challenges with approximately 1.4 million people living with HIV and ranking among the highest TB burden countries globally. Simultaneously, government initiatives supporting healthcare sector development and the increasing demand for quality…
PR Newswire
23/06/2025

Atrogi announces Cell paper highlighting transformative potential of…

Additionally, when combined with GLP-1 receptor agonists, ATR-258 avoids the critical shortcomings of current obesity and diabetes treatments by preventing the muscle loss typically associated with these therapies. Additionally, when combined with GLP-1 receptor agonists, ATR-258 avoids the critical shortcomings of current obesity and diabetes treatments by preventing the muscle loss typically associated with these therapies. Associate ProfessorMorten Hostrupfrom theUniversity of...
PR Newswire
23/06/2025

Dialysis Equipment Market Size to Reach USD 19.14 Billion by 2031, Growing Cases…

Technology is becoming the principal engine of growth, where AI-powered monitoring systems allow patients to have real-time monitoring of their dialysis cycle while automatically adjusting treatment parameters to optimize fluid removal and electrolyte balance. Portable and home-based dialysis devices have improved patient autonomy from dialysis centers and have also afforded flexibility in treatment schedules. This is a paradigm shift in the global landscape of the dialysis process. ...
PR Newswire
23/06/2025

Medical Endoscopes Market Size to Surpass USD US$ 22.46 Billion by 2031…

Technology is increasingly influencing the medical endoscopes market. The enhancement of endoscopic imaging with artificial intelligence (AI)-based functionalities, including real-time enhancement, automated detection, and decision support, will change clinical work flow by increase diagnostic performance, enhancing procedural efficiency, and making high quality care more effective and reduce variability. This signifies a large shift in healthcare, where introducing smart technologies provide…
PR Newswire
23/06/2025

Laparoscopic Devices Market Size to Hit US$ 26.61 billion by 2031, Growing Cases…

Technology is becoming the principal engine of growth, where AI-assisted robotic procedures also lower the chance for surgical errors, facilitate faster recovery timelines, and improved patient outcomes by enhancing surgical procedures and decreasing tissue trauma. Key driving force for the laparoscopic devices market is the increasing demand for minimally invasive surgeries (MIS), which include greatly beneficial outcomes to the patient and efficiencies in healthcare expense. Technology is...
PR Newswire
23/06/2025

Pressure Monitoring Market worth $25.48 billion by 2032 with 8.3% CAGR |…

Browse in-depth TOC on "Pressure Monitoring Market" Browse in-depth TOC on "Pressure Monitoring Market" 400 - Tables 380 - Figures 500 - Pages By products,the blood pressure monitoring devices market is experiencing significant growth, driven by several interconnected factors. The primary factor is the rising global prevalence of hypertension and cardiovascular diseases, which require regular monitoring for effective management. According to the World Health Organization,...
PR Newswire
23/06/2025

Côte d'Ivoire In Vitro Diagnostics Market Set to Grow from USD 21.5 Million to…

This growth trajectory reflects the nation's commitment to strengthening healthcare infrastructure while addressing the significant burden of infectious diseases through advanced diagnostic capabilities and expanded access to quality healthcare services across both urban and rural populations. This growth trajectory reflects the nation's commitment to strengthening healthcare infrastructure while addressing the significant burden of infectious diseases through advanced diagnostic capabilities...
PR Newswire
23/06/2025

Booming Advanced Wound Care Market Forecasted to Hit $14.87 Billion by 2030 with…

For More Information and To Stay Updated on The Latest Developments in The Global Advanced Wound Care Market Size, Download FREE Sample Pages: https://www.theresearchinsights.com/request_sample?id=649 For More Information and To Stay Updated on The Latest Developments in The Global Advanced Wound Care Market Size, Download FREE Sample Pages: https://www.theresearchinsights.com/request_sample?id=649 Market Overview and Growth Trajectory: Advanced Wound Care Market...
PR Newswire
23/06/2025

Ferric Pyrophosphate Market is expected to generate a revenue of USD 2.89…

The Ferric Pyrophosphate Market is witnessing steady growth due to its widespread usage in food fortification, pharmaceuticals, and dietary supplements. Growing awareness regarding iron deficiency and an increasing focus on preventive healthcare are further propelling market expansion. The Ferric Pyrophosphate Market is witnessing steady growth due to its widespread usage in food fortification, pharmaceuticals, and dietary supplements. Growing awareness regarding iron deficiency and an...
PR Newswire
23/06/2025

Transactions under Novonesis’ share buyback program

Please read the full announcement in PDF Attachment 2025_34_Share_buyback_program
Nasdaq GlobeNewswire
23/06/2025

Major shareholder announcement

Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital attached to shares and share capital through financial instruments. Per June 19, 2025, BlackRock, Inc. has adjusted its holding of shares to an equivalent of 23,343,678 shares, corresponding to 4.98% (previously 5.02%) of the total share capital attached to shares. The combined total of share capital...
Nasdaq GlobeNewswire
23/06/2025

Transactions in Connection with Share Buy-back Program

Company Announcement COPENHAGEN, Denmark; June 23, 2025 – Genmab A/S (Nasdaq: GMAB).On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program is expected to be completed no later than July 10, 2025.The following transactions were executed under the program from June 16 to June 20, 2025: Trading PlatformNo...
Nasdaq GlobeNewswire
23/06/2025

Portable Blender Market to Reach $0.29 Billion by 2032, Growing at a CAGR of…

The robust growth of the portable blender market is driven by the increasing consumer demand for on-the-go food and beverages amid busy modern lifestyles. The market's expansion is fueled by rising adoption of portable kitchen appliances, explosive growth in e-commerce channels, and the integration of smart features in portable blending devices across key global markets. The robust growth of the portable blender market is driven by the increasing consumer demand for on-the-go food and…
PR Newswire
23/06/2025

Emollient Market worth $4.08 billion by 2030 - Exclusive Report by…

280 – Tables60 – Figures250 – Pages 280 – Tables 60 – Figures 250 – Pages Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=177614531 The growing shift toward organic and sustainable personal care products is significantly driving the demand for natural emollients like shea butter, jojoba oil, and squalane. Consumers are increasingly focused on clean-label formulations that emphasize safety, transparency, and environmental responsibility. This...
PR Newswire
23/06/2025

Inside information: Preliminary result of Bioretec Oy's rights issue

TAMPERE, Finland, June 23, 2025 /PRNewswire/ -- Bioretec Ltd ("Bioretec" or the "Company") announced on 28 May 2025 that the Board of Directors of Bioretec has decided to offer Bioretec's shareholders up to 6,156,618 new shares (the "New Shares") for subscription primarily on the basis of shareholders' pre-emptive subscription right in the same proportion as they already hold shares in the Company and secondarily by other shareholders or by other persons (the…
PR Newswire
23/06/2025

Cell Study by SDU and PKU Researchers Reveals Novel Mechanism to Regulate…

This research is the first to reveal that the microbial-derived bile acid Trp-CA improves glucose homeostasis by activating MRGPRE. It provides a new potential drug target and therapeutic strategy for Type 2 Diabetes (T2D) treatment. Furthermore, the identification of the microbial origin of Trp-CA offers a new microbial therapeutic strategy for diabetes intervention. This research is the first to reveal that the microbial-derived bile acid Trp-CA improves glucose homeostasis by activating…
PR Newswire
23/06/2025

ITM and Debiopharm Announce First Patient Imaged in New Study Arm of Phase 1/2…

New study arm (Part D) is part of the broad clinical development plan of the ITM-91/ITM-94 theranostic program in patients with Carbonic Anhydrase IX (CAIX)-expressing tumors Part D builds on promising imaging data demonstrated in Part A of the study for ITM-94, a Gallium-68 ( 68 Ga)-labeled PET imaging candidate, as a diagnostic agent for early-stage clear cell renal cell carcinoma (ccRCC)Together with ITM-91, a Lutetium-177 ( 177 Lu)-labeled radiotherapeutic candidate, ITM-94 is a...
Nasdaq GlobeNewswire
23/06/2025

Herspiegel Acquires Decisive Consulting to Expand Global Life Sciences…

Known for its bold, creative problem-solving, Decisive Consulting helps life sciences companies challenge convention to drive breakthrough market access. Now united with the recently acquired FIECON's industry-leading HEOR and HTA expertise and Herspiegel's proven U.S. market access and commercialization capabilities, the combined set of commercialization services helps clients navigate complexity and seize opportunity from early asset strategy to launch readiness and market optimization. This…
PR Newswire
23/06/2025

European Medicines Agency Recommends Market Approval of AVT06, Alvotech’s…

REYKJAVIK, ICELAND and LONDON, UK (June 23, 2025)— Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human use (CHMP) adopted a positive opinion...
Nasdaq GlobeNewswire
23/06/2025

Final Data from Teva’s PEARL Real-World Study Reinforce the Long-term…

Final analysis of PEARL real world migraine prevention study presented at 11th Congress of the European Academy of Neurology (EAN 2025) Congress in Helsinki 1 ,2 Fremanezumab demonstrated sustained effectiveness and a favourable safety and tolerability profile over the two-year study period 1 ,2 Injection adherence remained high throughout the study(~90%), while over 75% of patients completed the study duration 1TEL AVIV, Israel, June23, 2025(GLOBE...
Nasdaq GlobeNewswire
23/06/2025

HABA celebrates 40 years of camping comfort: from a workplace to global…

Growing with vision and craftsmanshipHABA provides innovative products that contribute to comfort and safety on the campsite. With their recognisable range of camping products such as adapters, sockets, cable reels, inverters, solar panels and lighting, HABA makes camping carefree and comfortable. Thanks to years of experience, expert knowledge and a constant focus on improvement, HABA has become a trusted name in the leisure sector. Growing with vision and craftsmanshipHABA provides...
PR Newswire
23/06/2025

Enterome presents positive Phase 2 interim results in relapsed/refractory…

60% (12/20) complete response rate after treatment with EO2463 in combination with lenalidomide and rituximab (R 2 ) EO2463 plus R 2was well tolerated in patients with follicular and marginal zone lymphomaEO2463 plus R 2combination treatment resulted in higher-than-expected rates of complete remission so far in this study compared to historical data for R 2aloneParis, France – 23 June, 2025Enterome SA,a clinical-stage company developing first-in-class OncoMimics™...
Nasdaq GlobeNewswire
23/06/2025
Altri  Comunicati